[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fu Wai Hospital, Beijing, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,87,111,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100637597","stepwise-vs-standard-anticoagulation-for-af-patients-undergoing-cied-implantation-step-af-100637597",false,"NCT07616414","Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)","Stepwise Versus Standard Antithrombotic Strategies in Patients With Atrial Fibrillation at High Thromboembolic Risk Undergoing CIED Procedures (STEP-AF Trial)","STEP-AF","Inclusion Criteria:\n\n1. Aged 18 years or older at the time of screening, and able to provide written informed consent;\n2. Scheduled for any CIED procedure (implantation or generator replacement), including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices;\n3. Receiving NOAC therapy for at least 5 consecutive days prior to enrollment;\n4. Diagnosed with non-valvular atrial fibrillation (and\u002For atrial flutter) with a CHA₂DS₂-VASc score ≥2, or scheduled for cardioversion or defibrillation threshold testing during the CIED procedure.\n\nExclusion Criteria:\n\n1. Presence of active systemic or local infection at the time of screening;\n2. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin, or any other contraindication to NOAC use;\n3. Active bleeding (e.g., gastrointestinal bleeding);\n4. Severe thrombocytopenia, defined as platelet count \\\u003C 50 × 10⁹\u002FL at screening;\n5. Life expectancy \\\u003C1 year;\n6. Pregnancy.","ALL","18 Years",{"count":20,"type":21},424,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation regimen in patients with non-valvular atrial fibrillation at high thromboembolic risk (CHA₂DS₂-VASc score ≥2) undergoing cardiac implantable electronic device (CIED) implantation. A total of 424 eligible patients will be randomized 1:1 to either the stepwise anticoagulation group (reduced-dose NOAC from 24 hours post-surgery to day 7, followed by standard-dose NOAC) or the standard anticoagulation group (standard-dose NOAC resumed 24 hours post-surgery). The primary endpoint is the incidence of clinically significant pocket hematoma within 30 days after surgery. Secondary endpoints include individual components of the primary endpoint and other composite outcomes of major perioperative bleeding events. The study aims to provide evidence-based data for optimizing perioperative anticoagulation regimens in Chinese patients undergoing CIED implantation.",[27,28,29,30,31],"Non-valvular Atrial Fibrillation (NVAF)","Thromboembolism","Cardiac Implantable Electronic Device","Perioperative Bleeding","Hematoma Postoperative",[33,29,34,35,36,37,38,39,28,30,40,41,42],"Non-valvular atrial fibrillation","CIED","Perioperative Anticoagulation","Non-Vitamin K Antagonist Oral Anticoagulant","NOAC","Stepwise Anticoagulation","Postoperative hematoma","Randomized Controlled Trial","Edoxaban","Rivaroxaban","NOT_YET_RECRUITING","2026-05-23",{"date":46,"type":47},"2026-06-01","ACTUAL",{"date":49,"type":21},"2026-05-26",{"date":51,"type":21},"2026-12-31",{"name":53,"class":54},"Fu Wai Hospital, Beijing, China","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":55},"100635035","bachmann-bundle-pacing-for-prevention-of-new-onset-atrial-fibrillation-in-patients-with-heart-failure-100635035","NCT07547449","Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Failure","Clinical Efficacy of Bachmann Bundle Pacing on New-Onset Atrial Fibrillation in Patients With Cardiac Insufficiency","Inclusion Criteria:\n\n1. Aged between 18 and 70 years old;\n2. Diagnosis of chronic cardiac insufficiency according to current guidelines, and received guideline-directed medical therapy (GDMT) for at least 3 months;\n3. Have indications for CRT\u002FLBBP or ICD implantation, and expected atrial pacing ratio \\> 20%, including: Sinus rhythm, QRS duration \\> 120ms, LBBB, LVEF ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration ≥ 150ms, non-LBBB, LVEF ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration \\> 120ms, LBBB, LVEF 36%-50% with symptomatic heart failure; Symptomatic heart failure with LVEF ≤ 50% and expected ventricular pacing ratio \\> 20%; Symptomatic heart failure with LVEF ≤ 50% requiring ICD implantation for primary or secondary sudden death prevention, with atrial pacing indication due to sinus bradycardia or expected atrial pacing ratio \\> 20%;\n4. Patients with pacing-induced cardiomyopathy requiring upgrade therapy, in sinus rhythm, and requiring reimplantation of atrial lead;\n5. Signed written informed consent form approved by the ethics committee.\n\nExclusion Criteria:\n\n1. Expected survival time less than 12 months;\n2. Status after mechanical tricuspid valve replacement, or congenital heart disease (including dextrocardia, transposition of great arteries, single left persistent superior vena cava);\n3. Previous history of atrial fibrillation;\n4. Previous cardiac surgery, or requiring surgical treatment for severe structural heart disease within 1 year;\n5. Pregnancy, planned pregnancy, or heart transplantation;\n6. Patient refusal to participate in the study.","70 Years",{"count":65,"type":21},140,[24],"This is a multi-center, prospective, single-blind, randomized controlled clinical trial to evaluate the efficacy and safety of Bachmann bundle pacing (BBP) in preventing new-onset atrial fibrillation (AF) in patients with chronic cardiac insufficiency who have indications for cardiac resynchronization therapy with left bundle branch pacing (CRT\u002FLBBP) or implantable cardioverter defibrillator (ICD) implantation.\n\nA total of 110 eligible patients will be randomly assigned 1:1 to the BBP group or the traditional right atrial appendage (RAA) pacing group. All patients will receive guideline-directed medical therapy (GDMT) for at least 3 months and standardized follow-up for 12 months after device implantation. The primary endpoint is the incidence of new-onset AF within 12 months after implantation. Secondary endpoints include time to first new-onset AF, procedural success rate, changes in cardiac function parameters, and incidence of adverse events. This study aims to provide high-level evidence-based medical evidence for BBP as a new atrial pacing strategy to prevent AF in heart failure patients.",[69,70,71],"Heart Failure","Atrial Fibrillation (AF)","Cardiac Insufficiency",[73,74,75,76,77,78],"Bachmann Bundle Pacing","Right Atrial Appendage Pacing","Cardiac Resynchronization Therapy","Implantable Cardioverter Defibrillator","Physiological Pacing","New-Onset Atrial Fibrillation","2026-04-16",{"date":81,"type":47},"2026-04-23",{"date":83,"type":21},"2026-04",{"date":85,"type":21},"2028-04",{"name":53,"class":54},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":96,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":55},"100617271","risk-prediction-of-disease-progression-in-early-onset-coronary-atherosclerosis-100617271","NCT07316452","Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis","Inclusion Criteria:\n\n1. Age between 18 and 45 years at the time of enrollment.\n2. Presence of symptoms suggestive of coronary artery disease and completion of coronary computed tomography (CT) examination.\n3. Ability and willingness to provide written informed consent and to participate in follow-up assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to complete follow-up assessments.\n2. Inability to provide written informed consent.\n3. History of coronary revascularization, including percutaneous coronary intervention or coronary artery bypass grafting.\n4. Poor-quality coronary computed tomography images that are inadequate for reliable plaque assessment.\n5. Presence of severe systemic disease with limited life expectancy that may interfere with study follow-up.\n6. Pregnant or breastfeeding women.\n7. Participation in another clinical study that may interfere with the outcomes of this study.","45 Years",{"count":95,"type":21},10000,"3 Years","OBSERVATIONAL","This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults. The study will enroll approximately 10,000 participants aged 45 years or younger who undergo coronary CT scans at multiple hospitals across China.\n\nInformation collected at enrollment includes basic health information, cardiovascular risk factors, blood test results, medication use, lifestyle habits, and, for some participants, genetic data. Participants will undergo follow-up coronary CT scans after several years to evaluate changes in coronary artery plaque and disease progression.\n\nBy analyzing these clinical and imaging data, the study aims to identify factors associated with disease progression and to develop prediction models that may help estimate an individual's future risk of coronary plaque progression and cardiovascular events. The results of this study may contribute to improved risk assessment and early prevention strategies for coronary artery disease in young populations.",[100,101],"Coronary Disease","Young Adult","RECRUITING","2025-12-19",{"date":105,"type":47},"2026-01-05",{"date":107,"type":47},"2025-01-01",{"date":109,"type":21},"2028-01-01",{"name":53,"class":54},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100523074","phase-4-anti-inflammatory-therapy-for-recurrent-in-stent-restenosis-100523074","NCT06090890","Anti-inflammatory Therapy for Recurrent In-stent Restenosis","Safety and Efficacy of Low Dose Colchicine or Prednisone Combining With Standard Drug in Patients With Recurrent In-stent Restenosis: a Prospective, Randomized, Open-label Trial","Inclusion Criteria:\n\n1. CAD patients over 18 years old;\n2. At least one coronary artery lesion meets the RISR criteria: target lesion ≥ 2 ISRs (stenosis of lumen diameter within the stent segment and within 5mm near and far of the stent ≥ 50%);\n3. Intended intervention treatment for RISR lesions;\n4. Acceptable for standard secondary prevention drug therapy for coronary heart disease, including dual antiplatelet therapy (DAPT) and statins;\n5. Willing to participate in the trial and complete follow-up, signing an informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\n1. The previous interventional treatment situation is unknown;\n2. The mechanism of intracavitary imaging to clarify ISR is operator-related (poor stent adhesion, incomplete dilation, and stent fracture);\n3. Clearly diagnose vascular inflammatory diseases or connective tissue diseases (including arteritis, Behcet's disease, systemic lupus erythematosus, etc.) involving the coronary artery;\n4. Immunosuppressive drugs, including glucocorticoids, have been used in the past 30 days;\n5. There are contraindications to the use of prednisone or colchicine, including: serious infectious diseases, including active infection, hepatitis B, hepatitis C or AIDS patients; Hematological diseases, such as thrombocytopenia, severe anemia, leukemia, etc; Uncontrolled diabetes; Severe liver and kidney function damage; Active peptic ulcer or gastrointestinal bleeding; Severe osteoporosis (with previous pathological fractures); Inflammatory bowel disease or chronic diarrhea;\n6. A history of malignant tumors within 3 years;\n7. Cognitive impairment;\n8. Not willing to participate or follow up",{"count":119,"type":21},252,[121],"PHASE4","This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).",[124],"In-stent Restenosis",[126,124,127,128],"Anti-inflammatory therapy","Colchicine","Prednisone","2025-08-05",{"date":131,"type":47},"2025-08-08",{"date":133,"type":47},"2023-10-30",{"date":135,"type":21},"2027-10-29",{"name":53,"class":54},4,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":55},"100380995","phase-4-ticagrelor-with-low-dose-versus-regular-aspirin-in-patients-with-acute-coronary-syndrome-acs-at-high-risk-for-ischemia-after-percutaneous-coronary-intervention-100380995","NCT04240834","Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Randomized Controlled Study","LD-ASPIRIN","Inclusion Criteria:\n\n* ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent\n* Able and willing to provide informed consent and participate in 12 months follow-up period\n* Able to receive DAPT treatment\n* Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.\n\nClinical inclusion criteria:\n\n1. Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \\\u003C55 years old or in first-degree female relative \\\u003C65 years old)\n2. Repeated myocardial infarction\n3. Positive serum cardiac troponin I\u002FT\n4. Combined with at least one organ\u002Fsystem with atherosclerotic disease (e.g. intracranial or peripheral arteries)\n5. Type 2 diabetes mellitus under medication\n6. Chronic kidney disease (eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2 or CrCl\\\u003C60ml\u002Fmin)\n\nAngiographic Inclusion Criteria:\n\n1. LM lesion requiring stents\n2. Proximal LAD lesion(s) requiring stents\n3. Bypass grafts lesion(s) requiring stents\n4. Overall stent length ≥60 mm\n5. History of in-stent thrombosis\n6. Bifurcation lesions requiring at least 2 stents\n7. Over two vessels lesions requiring stents\n8. Calcified target lesion(s) requiring atherectomy\n9. The intraoperative occurrence of no-reflow or slow-flow\n10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)\n\nExclusion Criteria:\n\n* Need for chronic oral anticoagulation\n* With cardiomyopathy（HCM\u002FDCM\u002FRCM）\n* With severe ventricular arrhythmia requiring ICD implantation\n* With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)\n* With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）\n* With hematological disorders（thrombocytopenia, severe anemia, leukaemia）\n* With severe liver disease or kidney failure\n* With malignant tumor\n* With cognitive impairment\n* Unable or unwilling to provide informed consent or undergo follow-up",{"count":147,"type":21},1220,[121],"The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.",[151,152],"Acute Coronary Syndrome","Interventional Cardiology",[154,155,156,157,158],"ACS","PCI","DAPI","Aspirin","Ticagrelor","2024-06-15",{"date":161,"type":47},"2024-06-18",{"date":163,"type":47},"2021-02-01",{"date":165,"type":21},"2026-12",{"name":53,"class":54},""]